⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLTX News
MoonLake Immunotherapeutics Class A Ordinary Shares
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
businesswire.com
MLTX
MLTX INVESTIGATION ALERT: MoonLake Immunotherapeutics Trial Results Triggers Securities Fraud Investigation after Stock Plummets 90% -- Investors Urged to Contact BFA Law
businesswire.com
MLTX
MLTX
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
globenewswire.com
MLTX